Charles Cardon is a partner in the Corporate Department of the Paris office of Paul Hastings.
Charles' practice focuses on mergers and acquisitions for listed and non-listed companies, securities law and private equity transactions. He has significant experience advising French companies on their external growth projects in the U.S. and in Latin America.
He advises public companies in the context of their takeover bids (as advisor of target companies, bidders or shareholders), governance matters, disclosure requirements and relationship with shareholders as well as corporate law matters.
In private equity, Charles has developed a high level of experience in advising funds in a wide range of transactions, including LBO and stock exchange related deals, such as acquisition of a public target company by way of PtoP and IPO exit.
He is widely published and is a visiting professor at the Sorbonne-Assas International Law School and at the University of Paris I Panthéon-Sorbonne on issues pertaining to international takeovers, company law and securities law.
Accolades and Recognitions
Charles Cardon is an 'excellent professional who delivers a thoughtful but fast service, pragmatic and enthusiastic service, in the interest of the client.' Legal 500 2021
Ranked in 2020 by The Best Lawyers in Corporate M&A for France
Recognised in M&A and Private Equity for France by IFLR1000, 2019
University of Paris 1 Panthéon-Sorbonne, Master 2, 2004
ESSEC Business School, 2004
University Paris I: Panthéon-Sorbonne, M1, 2003
Member of the Paris Bar
Private Equity Transactions
Astorg in connection with the acquisition of stakes in Echosens.
Five Arrows in connection with the acquisition of A2MAC1.
TowerBrook in connection with the acquisition of Infopro Digital.
3i, Nixen, TCR Capital, CM-CIC Investissement and Omnes Capital in connection with the sale of Labco to Civen.
Management of group In'Tech Medical in connection with the secondary LBO by Eurazeo PME.
M&A Acquisitions / Sales
Generali in connection with the acquisition of Sycomore.
Eurovia in connection with the acquisition of the U.S. plants and paving assets from Lane.
Management team of Thermocoax in connection with the sale of the group to Spirax Group.
Founders and managers of laboratories NHCO Nutrition in connection with the sale of the company to Chiesi Group.
Vexim in connection with the cash tender offer initiated by Stryker.
Medtech in connection with the cash tender offer initiated by Zimmer Biomet.
Atos in connection with its cash tender offer and squeeze-out offer on Bull.
Vinci in connection with its cash tender offer followed by a squeeze-out offer on Entrepose Contracting.
Guyenne et Gascogne in connection with the cash tender offer and public exchange offer initiated by Carrefour.